Türkdoğan Dilşad, Öztürk Gülten
Medical Faculty, Department of Neurology, Marmara University, Istanbul, Turkey.
Acta Neurol Belg. 2022 Feb;122(1):51-57. doi: 10.1007/s13760-021-01606-4. Epub 2021 Mar 29.
Clobazam (CLB) is an effective anticonvulsant used as an adjunctive treatment for several seizures and epilepsy syndromes. Data are limited on efficacy and safety of CLB as add-on therapy for epileptic encephalopaties (EEs) other than Lennox-Gastaut syndrome (LGS). This retrospective study aimed to assess efficacy and safety of long-term CLB add-on therapy for various EE syndromes. Data on CLB add-on therapy were assessed in 74 children (60.8% male) after 3 months (early) and 12 months (late) follow-up as well as in 57 (77%) patients who had been on CLB therapy longer than 12 months (mean:39.11 ± 30.29; range:12-129 months) (very late) were reported. Data on CLB add-on therapy were assessed in 74 children (60.8% male) after 3 months (early) and 12 months (late) follow-up as well as in 57 (77%) patients who had been on CLB therapy longer than 12 months (mean:39.11 ± 30.29; range:12-129 months) (very late) were reported. Good response rate (> 50%) for seizures was achieved in 24% at early follow-up, 30% at late follow-up, and 35% during very late follow-up. Complete seizure remission was achieved for 15% seizures; 72.7% occurred at very late follow-up. Myoclonic seizures were the most responsive (35%); this response increased during late follow-up (46%), whereas 27.3% of myoclonic-atonic/atonic seizures had good response at early and very late follow-up. At late follow-up, comparison of mean effective doses of CLB did not show significant difference among types of seizures with good response. Adverse effects reported in 15% of patients did not require stopping CLB therapy. Generalized epileptogenic potentials significantly decreased while focal epileptogenic potentials significantly increased at first year of treatment in comparison to basal EEG findings (p < 0.001). CLB should be considered as an optional antiepileptic that is well tolerated, particularly in EEs with myoclonic and myoclonic-atonic/atonic seizures.
氯巴占(CLB)是一种有效的抗惊厥药物,用作多种癫痫发作和癫痫综合征的辅助治疗。除Lennox-Gastaut综合征(LGS)外,关于氯巴占作为癫痫性脑病(EEs)附加疗法的疗效和安全性的数据有限。这项回顾性研究旨在评估长期氯巴占附加疗法对各种EE综合征的疗效和安全性。报告了74名儿童(60.8%为男性)在3个月(早期)和12个月(晚期)随访后以及57名(77%)接受氯巴占治疗超过12个月(平均:39.11±30.29;范围:12 - 129个月)(极晚期)的患者的氯巴占附加疗法数据。报告了74名儿童(60.8%为男性)在3个月(早期)和12个月(晚期)随访后以及57名(77%)接受氯巴占治疗超过12个月(平均:39.11±30.29;范围:12 - 129个月)(极晚期)的患者的氯巴占附加疗法数据。早期随访时癫痫发作的良好反应率(>50%)为24%,晚期随访时为30%,极晚期随访时为35%。15%的癫痫发作实现了完全缓解;72.7%发生在极晚期随访时。肌阵挛性发作反应最为明显(35%);这种反应在晚期随访时有所增加(46%),而27.3%的肌阵挛 - 失张力/失张力发作在早期和极晚期随访时有良好反应。在晚期随访时,对有良好反应的癫痫发作类型,氯巴占平均有效剂量的比较未显示出显著差异。15%的患者报告有不良反应,但无需停用氯巴占治疗。与基础脑电图结果相比,在治疗的第一年,全身性癫痫源性电位显著降低,而局灶性癫痫源性电位显著增加(p < 0.001)。氯巴占应被视为一种耐受性良好的可选抗癫痫药物,尤其适用于伴有肌阵挛性和肌阵挛 - 失张力/失张力发作的EEs。